Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

GIST under imatinib therapy.

Raf Sciot1, Maria Debiec-Rychter

  • 1Department of Pathology, University Hospital, Catholic University of Leuven, Leuven, Belgium. raf.sciot@uz.kuleuven.ac

Seminars in Diagnostic Pathology
|December 30, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Renal allograft malakoplakia mimicking malignancy: the value of combined morphological and functional imaging.

Clinical kidney journal·2026
Same author

Urokinase Plasminogen Activator Receptor-Associated Protein (uPARAP) as a Potential Next Generation Molecular Target for Treatment of Gastrointestinal Stromal Tumors (GIST).

International journal of cancer·2026
Same author

Milk and honey: how skin changes reveal the deeper dangers of nutritional deficiencies.

Acta clinica Belgica·2026
Same author

Cellular Angiofibroma of the Prostate.

IJU case reports·2025
Same author

A morphomolecular study of 175 'USP6-associated neoplasms': The USP6 fusion partner strongly depends on morphology and location.

Histopathology·2025
Same author

Reply to Taal et al. Comment on "Iasella et al. Close Follow-Up of Patients with Neurofibromatosis Type 1 Reduces the Incidence of Malignant Peripheral Nerve Sheath Tumour. <i>Cancers</i> 2025, <i>17</i>, 1306".

Cancers·2025
Same journal

Update on the molecular pathology of the distinctive giant cell, fibro-osseous and bone forming lesions of the jaws.

Seminars in diagnostic pathology·2026
Same journal

Update on the molecular pathology and classification of odontogenic cysts and tumours.

Seminars in diagnostic pathology·2026
Same journal

MDM2 gene amplification in surgical pathology: biology, diagnostic utility, and clinical relevance in the modern era.

Seminars in diagnostic pathology·2026
Same journal

When three negatives equal a positive: Molecular updates of triple-negative breast carcinomas with favorable prognoses.

Seminars in diagnostic pathology·2026
Same journal

Old school, new insight: Revisiting histomorphology in the modern era of prostate cancer risk stratification.

Seminars in diagnostic pathology·2026
Same journal

Recent advances in genetic predisposition to primary testicular tumors.

Seminars in diagnostic pathology·2026
See all related articles

Imatinib mesylate improves gastrointestinal stromal tumor (GIST) prognosis for many patients. This review explores GIST response, resistance, and phenotypic changes under imatinib treatment, focusing on KIT mutations.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Gastrointestinal stromal tumors (GIST) prognosis significantly improved with imatinib mesylate, achieving 70-85% disease control.
  • Treatment response is linked to specific mutations in KIT or Platelet-Derived Growth Factor Receptor (PDGFR).
  • Secondary resistance to imatinib, occurring after initial response, presents a growing clinical challenge.

Purpose of the Study:

  • To review available data on the phenotype and genotype of GIST treated with imatinib.
  • To analyze GIST characteristics in both responding/stable and resistant cases.
  • To highlight significant phenotypic and immunophenotypic alterations in GIST during imatinib therapy.

Main Methods:

  • Literature review of studies on imatinib treatment in GIST.

Related Experiment Videos

  • Analysis of genotypic data (KIT/PDGFR mutations) and phenotypic characteristics.
  • Comparative analysis of responding/stable versus resistant GIST cases.

    • Main Results:

    • Imatinib efficacy is mutation-dependent, with varying response rates.
    • Secondary resistance mechanisms are under investigation.
    • Significant immunophenotypic changes can occur in GIST under imatinib treatment.

    Conclusions:

    • Understanding genotype-phenotype correlations is crucial for optimizing imatinib therapy in GIST.
    • Further research into resistance mechanisms is needed to improve long-term patient outcomes.
    • Monitoring phenotypic shifts may offer insights into treatment response and resistance.